Dydrogesterone use during pregnancy: Overview of birth defects reported since 1977

Early Human Development

Volumn 85, Issue 6, 2009, Pages 375-377

  Queisser Luft, Annette ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Birth defects; Congenital malformations; Dydrogesterone; Pregnancy; Progestogen

Indexed keywords

DYDROGESTERONE;

ARTICLE; BIRTH DEFECT; CONGENITAL MALFORMATION; DRUG FATALITY; DRUG USE; EYE MALFORMATION; FEMALE; HUMAN; IMMINENT ABORTION; MUSCULOSKELETAL DISEASE; NEURAL TUBE DEFECT; PREGNANCY; RECURRENT ABORTION; UROGENITAL TRACT DISEASE; VIRILIZATION;

ABNORMALITIES, DRUG-INDUCED; ADVERSE DRUG REACTION REPORTING SYSTEMS; DYDROGESTERONE; FEMALE; HUMANS; MATERNAL EXPOSURE; PREGNANCY; PROGESTINS;

EID: 67349217402     PISSN: 03783782     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.earlhumdev.2008.12.016     Document Type: Article

References (13)

1. National Center on Birth Defects and Developmental Disabilities [online]. Available from URL: http://cdc.gov [Accessed Aug 2006].
2. Omar M.H., Mashita M.K., Lim P.S., and Jamil M.A. Dydrogesterone in threatened abortion: pregnancy outcome. J Steroid Biochem Mol Biol 97 (2005) 421-425
3. El-Zibdeh M.Y. Dydrogesterone in the reduction of recurrent spontaneous abortion. J Steroid Biochem Mol Biol 97 (2005) 431-434
4. Chakravarty B.N., Shirazee H.H., Dam P., Goswami S.K., Chatterjee R., and Ghosh S. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J Steroid Biochem Mol Biol 97 (2005) 416-420
5. Tausk M. A general summary of dydrogesterone, a derivative of retroprogesterone. In: Tausk M. (Ed). International Encyclopaedia of Pharmacology and Therapeutics. Section 48. Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Drugs vol. II (1972), Pergamon Press, Oxford, New York 481
6. Roberts L.F., and West R.J. Teratogenesis and maternal progesterone. Lancet 2 (1977) 982
7. El Zibdeh M.Y. Randomised study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone (dydrogesterone) and human chorionic gonadotrophin (hCG). Fertil Steril 70 (1998) 77-78
8. Stabile M., Bianco A., Iannuzzi S., Buonocore M.C., and Ventruto V. A case of suspected teratogenic holoprosencephaly. J Med Genet 22 (1985) 147-149
9. Sasco A.J., Gendre I., Verbier-Naneix C., Soulier J.L., Raffi F., Satgé D., et al. Neonatal neuroblastoma and in utero exposure to progestagens. Int J Risk Saf Med 11 (1998) 121-128
10. Resseguie L.J., Hick J.F., Bruen J.A., Noller K.L., O'Fallon W.M., and Kurland L.T. Congenital malformations among offspring exposed in utero to progestins, Omsted County, Minnesota 1936-1974. Fertil Steril 43 (1985) 514-519
11. Katz Z., Lancet M., Skornik J., Chemke J., Mogilner B.M., and Klinberg M. Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynecol 65 (1985) 775-780
12. Martínez-Frías M.L., Rodríguez-Pinilla E., and Bermejo E. Prenatal exposure to sex hormones: a case control study. Teratology 57 (1998) 8-12
13. Raman-Wilms L., Tseng A.L., Wighardt S., Einarson T.R., and Koren G. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. Obstet Gynecol 85 (1995) 141-149